CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
EA8184 ECOG-ACRIN A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers Cancer Prevention and Control CIRB
EA8185 ECOG-ACRIN Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in clinical Stage 3, Node PosItive bladdeR cancEr (INSPIRE) Adult CIRB - Late Phase Emphasis
EA8191 ECOG-ACRIN Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence Adult CIRB - Late Phase Emphasis
EA8192 ECOG-ACRIN A Phase II/III trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy Adult CIRB - Late Phase Emphasis
EA8211 ECOG-ACRIN Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR) Adult CIRB - Late Phase Emphasis
EA8212 ECOG-ACRIN A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) Adult CIRB - Late Phase Emphasis
EA8231 ECOG-ACRIN A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer Adult CIRB - Late Phase Emphasis
EA9131 ECOG-ACRIN A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) Cancer Prevention and Control CIRB
EA9152 ECOG-ACRIN A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Adult CIRB - Late Phase Emphasis
EA9161 Alliance A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Adult CIRB - Late Phase Emphasis